Fulcrum Ventures invests $1.25M in Path-Tec

Fulcrum Ventures announced today that they invested $1.25 million in Path-Tec, LLC.  Founded in 2005, Path-Tec provides clinical, pharmaceutical and research labs with a turnkey solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia, Path-Tec positions itself as a complete outsourcing solution for labs.

The company will use the funds to expand its operating infrastructure, strengthen its technology offering and provide working capital for its rapid growth. "Path-Tec is well positioned to rapidly expand both its current product offering as well as its customer base," said Kevin Boykin, CEO of Path-Tec. "We are thrilled to be working with Fulcrum Ventures and to have such a strong, experienced partner to support our growth."

"We believe that Path-Tec can be a leader in this expanding industry.  The demand for routine and esoteric laboratory tests continues to increase.  Hospitals and reference labs are looking for a service provider who can provide customized kitting products as well as value added services, including supply chain visibility, inventory management and tracking" said Frank X. Dalton, General Partner at Fulcrum Ventures.

Source:

Fulcrum Ventures

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics